Product Description
Mechanisms of Action: PI3K Inhibitor,mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias|Lymphoma|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT01725139 | P1 |
Completed |
Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias |
2016-07-12 |
52% |
| NCT01248858 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2014-01-30 |
|
| FTIH | P1 |
Completed |
Lymphoma |
2012-12-12 |